“The newly released draft breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF) (1) correctly state that, as of September 2024, the final rule from the Food and Drug Administration (FDA) requires all U.S. mammography facilities to notify women if their breasts are dense or not dense, that dense tissue makes it harder to find cancer on a mammogram, and that it also raises the risk of developing breast cancer. For women with dense breasts, the FDA further requires notification that “in some people with dense tissue, other imaging tests in addition to mammography may help find cancers.” The USPSTF update just released erroneously concludes there is inadequate evidence to support adding screening US or MRI to mammography. Because insurance may not cover screening not recommended by the USPSTF, this needs to be addressed. People will be told the mammogram is limited in women with dense breasts and that other imaging tests can help, but affected women may be denied or unable to afford additional imaging tests because of lack of insurance coverage. An unintended consequence of the USPSTF update is that the benefit of finding cancer early may be limited to those women with substantial resources who can obtain potentially life-saving additional screening to find the many cancers missed on standard mammography.”